What does the termination of the Hart-Scott-Rodino waiting period mean for McKesson?

The termination of the waiting period signifies that the Department of Justice has completed its initial review of the transaction and has no antitrust concerns that would prevent it from proceeding. This is a critical regulatory milestone, allowing the companies to move forward with the transaction.

What is the expected impact of this development on the joint venture?

This development is a positive sign for the formation of the joint venture. It reduces the regulatory uncertainty surrounding the deal and brings McKesson closer to completing the transaction and realizing the strategic benefits of the combined healthcare information technology company.

When was the original agreement to form the joint venture announced?

The original agreement, a contribution and sale agreement, was dated as of June 28, 2016, and involved McKesson, Change Healthcare, Inc., and other affiliated parties.

MCK 8-K SEC Disclosure — Dec 21, 2016

Q: What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce that the U.S. Department of Justice has closed its antitrust review and terminated the waiting period under the Hart-Scott-Rodino Act for McKesson's previously announced transaction with Change Healthcare to form a healthcare information technology company.

Summary

McKesson Corporation (MCK) has filed an 8-K report on December 21, 2016, announcing a significant development regarding its previously announced agreement to form a healthcare information technology company with Change Healthcare Holdings, Inc. The key update is that the U.S. Department of Justice has closed its review and terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This termination of the antitrust review is a crucial step forward for the proposed joint venture. It signifies that regulators have not raised any objections to the transaction, paving the way for McKesson to proceed with its plan to combine its IT assets with Change Healthcare to create a new, leading healthcare information technology company. Investors should view this as a positive development, reducing regulatory uncertainty and bringing the transaction closer to completion.

Key Highlights

1U.S. Department of Justice has closed its antitrust review of the proposed transaction.
2The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has been terminated.
3This development removes a significant regulatory hurdle for the formation of the new healthcare IT company.
4The transaction involves McKesson's contribution and sale of assets to form a joint venture with Change Healthcare.
5The press release announcing this update was issued on December 21, 2016.
6This is a positive step towards the completion of the joint venture, reducing execution risk for investors.

MCKESSON CORP 8-K Report, Corporate Update (Dec 21, 2016)

Summary

Key Highlights

Frequently Asked Questions